Crystalline Salt Forms for Mitochondrial ETC Targeting
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing antioxidants fail to selectively target the electron transport chain (ETC) of mitochondria, leading to insufficient ATP production and excessive ROS production, which contributes to mitochondrial dysfunction and associated diseases.
Innovation Solution
Development of crystalline salts of Compound I, such as mesylate, tosylate, fumarate, and others, which can modulate the physicochemical properties of the compound, allowing it to selectively target the ETC and restore efficient oxidative phosphorylation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Object-affected harmful factors
If natural antioxidants such as coenzyme Q and vitamin E are used to protect cells from ROS damage, then cellular protection is improved, but the ability to selectively target the ETC and restore efficient oxidative phosphorylation is insufficient
Solution Approach 1:
The patent applies local quality by designing Compound I with specific structural features (hydrophobic domain and hydrophilic domain) that enable selective localization to the mitochondrial ETC. The hydrophobic domain facilitates insertion into the lipid bilayer near the ETC, while the hydrophilic domain positions the reactive center at the aqueous-lipid interface where it can specifically interact with ETC components, achieving localized action rather than general antioxidant protection.
Solution Approach 2:
The patent employs parameter changes by modifying the molecular structure of Compound I to optimize its partition coefficient and redox potential. These parameter adjustments enable the compound to concentrate at the ETC location and maintain the appropriate oxidation-reduction state to specifically target ETC dysfunction without interfering with other cellular processes.
2Object-affected harmful factors
If antioxidants are used to reduce ROS levels, then cellular protection is improved, but ROS levels may be reduced to unhealthy levels and the compound may not reach the ETC in sufficient concentrations
Solution Approach 1:
The patent applies local quality by designing Compound I with specific structural features (hydrophobic domain and hydrophilic domain) that enable selective localization to the mitochondrial ETC. The hydrophobic domain facilitates insertion into the lipid bilayer near the ETC, while the hydrophilic domain positions the reactive center at the aqueous-lipid interface where it can specifically interact with ETC components, achieving localized action rather than general antioxidant protection.
Solution Approach 2:
The patent employs an intermediary approach by using the amphipathic structure of Compound I as a mediator that bridges the aqueous and lipid phases. This structure acts as a carrier that transports the antioxidant function specifically to the ETC location, ensuring sufficient concentration at the target site without requiring high overall concentrations that would deplete ROS to unhealthy levels.
3Reliability
If crystalline salts of Compound I are developed to modulate physicochemical properties, then selective targeting of ETC and restoration of oxidative phosphorylation is improved, but the complexity of the patent increases with multiple salt forms and crystalline patterns
Solution Approach 1:
The patent applies segmentation by dividing the compound into multiple salt forms (hydrochloride, tosylate, mesylate, fumarate, etc.) and further dividing each salt into distinct crystalline patterns. This segmentation allows systematic optimization of physicochemical properties for different pharmaceutical formulations while maintaining the core active compound structure that provides ETC targeting capability.
Solution Approach 2:
The patent employs parameter changes by systematically varying the salt form and crystalline pattern to optimize key parameters such as solubility, stability, and bioavailability. Each crystalline form represents a specific parameter configuration that can be selected based on the desired pharmaceutical properties, enabling fine-tuned control over the compound's behavior in different formulations.
Data Source
AI summary
Disclosed are various crystalline salt forms of D-Arg-Dmt-Lys-Phe-NH2.